Varie
Santen Makes Waves at ESCRS 2019 With Significant Expansion Into Surgical Devices and Publication of Real-world Evidence in Dry Eye Disease
The 24-week results of PERSPECTIVE, an ongoing 12 month, non-interventional, multi-centre, European, prospective study have been presented at ESCRS 2019 (Tuesday 17 September, 14:48 to 14:56) as a poster. The study evaluated the effectiveness, tolerability and safety of cyclosporine A (CsA) 0.1% eye drop emulsion, marketed as IKERVIS , in controlling severe keratitis and other parameters including improvement of symptoms, in adult dry eye patients, who had previously failed to respond to artificial tear treatments. The interim analysis data demonstrated that CsA 0.1% eye drop emulsion provides an effective, well tolerated and safe treatment at Week 24, compared with baseline, in adults with dry eye disease (DED) and severe keratitis. Key findings include:
Beyond this, Santen EMEA is hosting a range of educational events, both as part of the scientific programme as well as on our exhibition booth with the continuation of our Booth Talks initiative. Led by a number of international experts in their field, this way of engaging delegates aims to create another congress environment for peer-to-peer best practice sharing.
In addition to our expansion into surgical devices, we are engaged in research to support patients following ophthalmic surgery. Prof. Francesco Bandello will discuss and introduce new data considering the optimal management of post-cataract infectious complications. The discussion will address whether the use of a new topical combination of levofloxacin and dexamethasone followed by dexamethasone alone is not inferior to the standard 2-week tobramycin and dexamethasone treatment in preventing and treating ocular inflammation and in averting infections after cataract surgery.
We are delighted to share these advancements with the community at ESCRS 2019 and look forward to interfacing with the ophthalmology to further address the clinical needs in the ophthalmology community.
As a specialised company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA ( Europe , Middle East and Africa ) region. With scientific knowledge and organisational capabilities nurtured over nearly 130 years, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society in more than 60 countries. For more information, please visit Santen websites www.santen.com ( Japan headquarters) and www.santen.eu (EMEA).
PRESERFLO is the new trademark of Innfocus MicroShunt . PRESERFLO MicroShunt will replace Innfocus MicroShunt in the future.